Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8101580 | 0.98 | LMNA (0.71) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3259897 | 0.98 | LMNA (0.71) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL18513329 | 0.91 | HTT (0.67) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL4173649 | 0.91 | HTT (0.62) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL13055383 | 0.91 | LMNA (0.80) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL535583 | 0.90 | HTT (0.74) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| Phosphoric Acid SCHEMBL30873514 | 0.89 | LMNA (0.60) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL667447 | 0.88 | HTT (0.72) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL5116842 | 0.88 | HTT (0.72) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL22123293 | 0.88 | HTT (0.67) | LMNASMN1; SMN2HTTTGM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113929739-B | Gly-Pro-Arg-Pro-NH ethoxycarbonyl warfarin, synthesis, activity and application thereof | 首都医科大学 | 2023-07-28 | — | — | CN | claimed |
| CN-218516724-U | N- (2-hydroxyethyl) carbamic acid benzyl ester purification device | 江苏吉泰肽业科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| CN-115093365-A | Synthesis method of lefenacin | 沈阳药科大学 | 2022-09-23 | — | — | CN | claimed |
| CN-113929739-A | Gly-Pro-Arg-Pro-NH ethoxycarbonyl warfarin, and synthesis, activity and application thereof | 首都医科大学 | 2022-01-14 | — | — | CN | claimed |
| US-11026889-B2 | Polymeric drug delivery systems for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-08 | — | — | US | claimed |
| US-20200246264-A1 | POLYMERIC DRUG DELIVERY SYSTEMS FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-08-06 | — | — | US | claimed |
| WO-2017100533-A1 | POLYMERIC DRUG DELIVERY SYSTEMS FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-15 | — | — | WO | claimed |
| CN-101805369-A | Preparation methods of distearoyl phosphatidyl ethanolamine and amino polyethylene glycol derivatives thereof | UNIV SOUTHEAST | 2010-08-18 | — | — | CN | claimed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | claimed |
| EP-2114866-A2 | GLYCEROL ESTER-FREE FUNCTIONALIZED VEGETABLE OIL DERIVATIVES AND THEIR LATEX COMPOSITIONS | University of Southern Mississippi (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008094503-A2 | GLYCEROL ESTER-FREE FUNCTIONALIZED VEGETABLE OIL DERIVATIVES AND THEIR LATEX COMPOSITIONS | UNIVERSITY OF SOUTH MISSISSIPPI (US) | 2008-08-07 | — | — | WO | claimed |
| US-20080183000-A1 | Glycerol ester-free functionalized vegetable oil derivatives and their latex compositions | UNIVERSITY OF SOUTHERN MISSISSIPPI, THE | 2008-07-31 | — | — | US | claimed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | claimed |
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | claimed |
| US-6288141-B1 | Ink compositions | XEROX CORPORATION | 2001-09-11 | — | — | US | claimed |
| US-6210816-B1 | Translucent xerographic recording substrates | XEROX CORPORATION | 2001-04-03 | — | — | US | claimed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | claimed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | claimed |
| JP-58049395-A | — | — | None | — | — | JP | disclosed |
| JP-61246196-A | — | — | None | — | — | JP | disclosed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-12552775-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4638446-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4384223-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3450450-B1 | VANCOMYCIN DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-06-05 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025103442-A1 | SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| WO-2025061148-A1 | HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2025-03-27 | — | — | WO | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025048714-A1 | A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-03-06 | — | — | WO | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| WO-2025003755-A1 | HELPER LIPIDS FOR NUCLEIC ACID DELIVERY | SANOFI (FR) | 2025-01-02 | — | — | WO | disclosed |
| EP-4217361-B1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | GREY WOLF THERAPEUTICS LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| US-12150948-B2 | Toll-like receptor ligands | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2024235133-A1 | POLYCYCLIC DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235130-A1 | POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4440701-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12110308-B2 | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| US-20240327356-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| CN-118638021-A | Ionizable lipid compound, liposome, lipid nanoparticle and application thereof | 丹塔舟子医药技术(广州)有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240300900-A1 | HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES AND METAL-FREE CLICK REACTIONS WITH THESE HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20240300976-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024177424-A1 | NOVEL IONIZABLE LIPID AND LIPID NANOPARTICLE CONTAINING SAME | 에스티팜 주식회사 | 2024-08-29 | — | — | WO | disclosed |
| US-20240279221-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHROEDINGER INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4410802-A2 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORPORATION (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2024137607-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118234709-A | Hydrophilic azadibenzocyclooctyne derivatives and metal-free click reactions with these hydrophilic azadibenzocyclooctyne derivatives | 豪夫迈·罗氏有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4384224-A1 | CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-111867623-B | TOLL-like receptor ligands | 英尼穆内公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3752182-B1 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-114591361-B | Preparation method of (R) -glycerophosphatidylethanolamine | 苏州昊帆生物股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4346815-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| CN-117715642-A | Heterocyclic compounds and methods of use | 薛定谔公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4335496-A2 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| WO-2024040169-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| EP-4320103-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4304655-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| EP-3362089-B1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | SANOFI PASTEUR (FR) | 2023-12-06 | — | — | EP | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116891484-A | Condensed ring compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116867785-A | Compounds and uses thereof | 福宏治疗公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116813518-A | Synthesis method of nemaltevir chiral intermediate | 江苏暨明医药科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4247815-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| EP-4217361-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2023-08-02 | — | — | EP | disclosed |
| CN-113929739-B | Gly-Pro-Arg-Pro-NH ethoxycarbonyl warfarin, synthesis, activity and application thereof | 首都医科大学 | 2023-07-28 | — | — | CN | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| CN-110343117-B | Process for the preparation of artemisinin derivatives | 中国科学院上海药物研究所 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-116171279-A | Macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023083895-A1 | HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES AND METAL-FREE CLICK REACTIONS WITH THESE HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023049816-A9 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115996755-A | Bifunctional molecules and methods of use thereof | 旗舰创业创新VI有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4161917-A1 | GRK2 INHIBITORS AND USES THEREOF | Cygnal Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916219-A | Bifunctional molecules and methods of use thereof | 旗舰创业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115916262-A | Bifunctional molecules and methods of use thereof | 旗舰创业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2023049816-A2 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230099027-A1 | VIRUCIDAL COMPOSITIONS AND USE THEREOF | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2023-03-30 | — | — | US | disclosed |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230064920-A1 | PROCESS OF PREPARING ARACHIDONOYLETHANOLAMINE ANALOGUES | TRAVECTA THERAPEUTICS PTE. LTD. (SG) | 2023-03-02 | — | — | US | disclosed |
| EP-4138858-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4138857-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-218516724-U | N- (2-hydroxyethyl) carbamic acid benzyl ester purification device | 江苏吉泰肽业科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-218516724-U | N- (2-hydroxyethyl) carbamic acid benzyl ester purification device | 江苏吉泰肽业科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-218516724-U | N- (2-hydroxyethyl) carbamic acid benzyl ester purification device | 江苏吉泰肽业科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20230055805-A1 | TOLL-LIKE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-23 | — | — | US | disclosed |
| WO-2023017483-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017484-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| EP-4125935-A1 | VIRUCIDAL COMPOSITIONS AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126063-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-01-19 | — | — | US | disclosed |
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | SONATA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| CN-113024563-B | Pyrimido five-membered heterocyclic compound or pharmaceutically acceptable salt and isomer thereof, and preparation method, pharmaceutical composition and application thereof | 药康众拓(江苏)医药科技有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-115515604-A | Virucidal compositions and uses thereof | 洛桑联邦理工学院 | 2022-12-23 | — | — | CN | disclosed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | disclosed |
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022251497-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-115335373-A | Compound and use thereof | 福宏治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | US | disclosed |
| US-11484599-B2 | Polymer conjugate vaccines | THE UNIVERSITY OF CHICAGO (US) | 2022-11-01 | — | — | US | disclosed |
| CN-108770357-B | Polymer conjugate vaccines | 芝加哥大学 | 2022-10-28 | — | — | CN | disclosed |
| WO-2022217118-A1 | PYRIMIDINE BASED RAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115175735-A | Antiviral compounds | 吉利德科学公司 | 2022-10-11 | — | — | CN | disclosed |
| US-11458151-B2 | Toll-like receptor ligands | INIMMUNE CORPORATION (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220305135-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2022-09-29 | — | — | US | disclosed |
| CN-109071607-B | Vancomycin derivatives, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-09-27 | — | — | CN | disclosed |
| CN-115093365-A | Synthesis method of lefenacin | 沈阳药科大学 | 2022-09-23 | — | — | CN | disclosed |
| CN-115093365-A | Synthesis method of lefenacin | 沈阳药科大学 | 2022-09-23 | — | — | CN | disclosed |
| WO-2022189859-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-09-15 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-08-25 | — | — | US | disclosed |
| CN-114929691-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| EP-4039686-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114761383-A | Sulfonamide derivatives and uses thereof | 诺瑟拉有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022148879-A1 | QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF ACKR3 | STICHTING VU (NL) | 2022-07-14 | — | — | WO | disclosed |
| EP-4011870-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114591361-A | Preparation method of (R) -glycerol phosphatidylethanolamine | 苏州昊帆生物股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-108367062-B | Immunogenic compositions against staphylococcus aureus | 赛诺菲巴斯德有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3983388-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | Nodthera Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20220112225-A1 | ANANDAMIDE COMPOUNDS | TRAVECTA THERAPEUTICS PTE LTD (SG) | 2022-04-14 | — | — | US | disclosed |
| CN-111825695-B | Oxazolidinone compound, preparation method, application and pharmaceutical composition thereof | 中国科学院上海药物研究所 | 2022-04-12 | — | — | CN | disclosed |
| EP-3976617-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976061-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS | The University of Chicago (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022064187-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2022-03-31 | — | — | WO | disclosed |
| CN-114206355-A | Methods and compositions for treating cancer with cancer-targeting adjuvants | 芝加哥大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20220081737-A1 | POND REACTOR FOR RECOVERY OF METALS | CYCAD GROUP, LLC | 2022-03-17 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-113943330-A | Sugar-containing structure compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-01-18 | — | — | CN | disclosed |
| CN-113929739-A | Gly-Pro-Arg-Pro-NH ethoxycarbonyl warfarin, and synthesis, activity and application thereof | 首都医科大学 | 2022-01-14 | — | — | CN | disclosed |
| CN-113784754-A | Arachidonic acid ethanolamine compound | 特拉维克塔治疗私人有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021198139-A1 | VIRUCIDAL COMPOSITIONS AND USE THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-10-07 | — | — | WO | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11111237-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-09-07 | — | — | US | disclosed |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2021-08-05 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-08-05 | — | — | US | disclosed |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-07-29 | — | — | US | disclosed |
| CN-109069872-B | Polymeric drug delivery systems for the treatment of diseases | 得克萨斯州大学系统董事会 | 2021-07-13 | — | — | CN | disclosed |
| US-11052070-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-07-06 | — | — | US | disclosed |
| CN-107567438-B | Riluzole prodrugs and uses thereof | 拜尔哈文制药股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210188887-A1 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-11026889-B2 | Polymeric drug delivery systems for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021099554-A1 | PROCESS OF PREPARING ARACHIDONOYLETHANOLAMINE ANALOGUES | TRAVECTA THERAPEUTICS PTE. LTD. (SG) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021066578-A1 | BICYCLIC COMPOUND AND USE THEREOF | 에스케이바이오팜 주식회사 | 2021-04-08 | — | — | WO | disclosed |
| US-20210101892-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2021-04-08 | — | — | US | disclosed |
| US-10961278-B2 | Vancomycin derivative, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-03-30 | — | — | US | disclosed |
| US-10905681-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-20210023106-A1 | TOLL-LIKE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-28 | — | — | US | disclosed |
| EP-3752511-A1 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020249669-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| CN-112074298-A | Langerin+Cell targeting | 马克斯·普朗克科学促进协会 | 2020-12-11 | — | — | CN | disclosed |
| EP-2772480-B2 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2020-12-09 | — | — | EP | disclosed |
| CN-111867623-A | TOLL-like receptor ligands | 英尼穆内公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-09-17 | — | — | US | disclosed |
| US-10772946-B2 | Immunogenic compositions against S. aureus | SANOFI PASTEUR (FR) | 2020-09-15 | — | — | US | disclosed |
| CN-107428780-B | Benzodiazepine dimers, conjugates thereof, and methods of making and using | 百时美施贵宝公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3700901-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200246264-A1 | POLYMERIC DRUG DELIVERY SYSTEMS FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-08-06 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-10577481-B2 | Polymer | CANON KABUSHIKI KAISHA (JP) | 2020-03-03 | — | — | US | disclosed |
| CN-106061480-B | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2020-02-28 | — | — | CN | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| CN-110041383-A | Chondroitin sulfate oligosaccharides, preparation method and application | 中国医学科学院药物研究所 | 2019-07-23 | — | — | CN | disclosed |
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190153036-A1 | VANCOMYCIN DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190119267-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3424939-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| CN-109071607-A | Vancomycin derivatives, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2018-12-21 | — | — | CN | disclosed |
| US-20180305522-A1 | POLYMER | CANON KABUSHIKI KAISHA (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10093663-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2018-10-09 | — | — | US | disclosed |
| US-20180280491-A1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | SANOFI PASTEUR (FR) | 2018-10-04 | — | — | US | disclosed |
| US-10081626-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3362089-A1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | Sanofi Pasteur (FR) | 2018-08-22 | — | — | EP | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2772480-B1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9975903-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9957546-B2 | Vivo detection of phospholipase activation | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3299365-A1 | PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| EP-2957285-B1 | PHOSPHOLIPID COMPOUND CONTAINING UNSATURATED FATTY ACID DERIVATIVE HAVING CYCLOPROPANE RING | NISHIZAKI BIOINFORMATION RES INSTITUTE (JP) | 2018-01-10 | — | — | EP | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| CN-105367482-B | N acyl sulfonamides apoptosis accelerator | 阿斯利康(瑞典)有限公司 | 2017-12-12 | — | — | CN | disclosed |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349578-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170320856-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3239142-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-3022192-B1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| WO-2017100533-A1 | POLYMERIC DRUG DELIVERY SYSTEMS FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-15 | — | — | WO | disclosed |
| US-9676728-B2 | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-13 | — | — | US | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| US-9663509-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9630977-B2 | Cephalosporin derivatives and pharmaceutical compositions thereof | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-04-25 | — | — | US | disclosed |
| WO-2017064190-A1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | SANOFI PASTEUR (FR) | 2017-04-20 | — | — | WO | disclosed |
| EP-2970269-B1 | 2-(1H-INDOL-4-YLMETHYL)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBONITRILE DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-9617212-B2 | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors | CONTROLLED CHEMICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617212-B2 | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors | CONTROLLED CHEMICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617212-B2 | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors | CONTROLLED CHEMICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2855456-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066794-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2017-03-09 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2016202894-A1 | METHOD OF CONVERTING ALCOHOL TO HALIDE | UNIVERSITAET DES SAARLANDES (DE) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016202894-A1 | METHOD OF CONVERTING ALCOHOL TO HALIDE | UNIVERSITAET DES SAARLANDES (DE) | 2016-12-22 | — | — | WO | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9512152-B2 | Phospholipid compound containing unsaturated fatty acid derivative having cyclopropane ring | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| EP-3089963-A1 | 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20160311779-A1 | 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| CN-106061480-A | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2016-10-26 | — | — | CN | disclosed |
| US-9475806-B2 | Complement factor B inhibitors and uses there of | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| CN-104603127-B | Complement pathway modulators and uses thereof | 诺华股份有限公司 | 2016-10-05 | — | — | CN | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2016101118-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106105-A1 | AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160176863-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| EP-3022192-A1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| CN-105367482-A | N-acylsulfamide apoptosis accelerator | ASTRAZENECA AB | 2016-03-02 | — | — | CN | disclosed |
| US-20160024079-A1 | Complement Factor B inhibitors and uses there of | NOVARTIS AG (CH) | 2016-01-28 | — | — | US | disclosed |
| EP-2970269-A1 | 2-(1H-INDOL-4-YLMETHYL)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBONITRILE DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376213-A1 | PHOSPHOLIPID COMPOUND CONTAINING UNSATURATED FATTY ACID DERIVATIVE HAVING CYCLOPROPANE RING | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2957285-A1 | PHOSPHOLIPID COMPOUND CONTAINING UNSATURATED FATTY ACID DERIVATIVE HAVING CYCLOPROPANE RING | Nishizaki Bioinformation Research Institute (JP) | 2015-12-23 | — | — | EP | disclosed |
| US-9206172-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| CN-103153954-B | N-acylsulfonamide apoptosis promoters | ASTRAZENECA AB (SE) | 2015-11-25 | — | — | CN | disclosed |
| US-20150291579-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015095052-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150176211-A1 | AQUEOUS DISPERSIONS FOR USE AS COATINGS WITH VARIABLE WATER VAPOR PERMEANCE RATINGS | CERTAINTEED CORPORATION | 2015-06-25 | — | — | US | disclosed |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-9056874-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| WO-2015066241-A1 | 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| CN-104603127-A | Complement pathway modulators and uses thereof | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| EP-2855456-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8956876-B2 | Method for quantitatively detecting 8-OXO 2′-deoxyguanosine in aqueous sample solution with high sensitivity | TAS Project Co. Ltd (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8956876-B2 | Method for quantitatively detecting 8-OXO 2′-deoxyguanosine in aqueous sample solution with high sensitivity | TAS Project Co. Ltd (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8956876-B2 | Method for quantitatively detecting 8-OXO 2′-deoxyguanosine in aqueous sample solution with high sensitivity | TAS Project Co. Ltd (JP) | 2015-02-17 | — | — | US | disclosed |
| WO-2015009616-A1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-1885734-B1 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | NOVARTIS AG (CH) | 2015-01-14 | — | — | EP | disclosed |
| US-8927573-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| CN-101878208-B | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-10-15 | — | — | CN | disclosed |
| US-8846929-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846929-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140288112-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| CN-102653573-B | Anti-adsorption and long-circulation lipid molecule, preparation method and application thereof in fields of medicines and cosmetics | INST PROCESS ENG CAS | 2014-09-24 | — | — | CN | disclosed |
| WO-2014143638-A1 | 2-(1H-INDOL-4-YLMETHYL)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBONITRILE DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | NOVARTIS AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2772480-A1 | HIV REPLICATION INHIBITOR | Shionogi & Co., Ltd. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2706062-A2 | NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | LegoChem Biosciences, Inc. (KR) | 2014-03-12 | — | — | EP | disclosed |
| US-8664242-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140057357-A1 | METHOD FOR QUANTITATIVELY DETECTING 8-OXO 2'-DEOXYGUANOSINE IN AQUEOUS SAMPLE SOLUTION WITH HIGH SENSITIVITY | TAS Project Co. Ltd. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057357-A1 | METHOD FOR QUANTITATIVELY DETECTING 8-OXO 2'-DEOXYGUANOSINE IN AQUEOUS SAMPLE SOLUTION WITH HIGH SENSITIVITY | TAS Project Co. Ltd. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057357-A1 | METHOD FOR QUANTITATIVELY DETECTING 8-OXO 2'-DEOXYGUANOSINE IN AQUEOUS SAMPLE SOLUTION WITH HIGH SENSITIVITY | TAS Project Co. Ltd. (JP) | 2014-02-27 | — | — | US | disclosed |
| EP-2690429-A1 | METHOD FOR QUANTITATIVELY DETECTING 8-OXO-2'-DEOXYGUANOSINE IN AQUEOUS SAMPLE SOLUTION WITH HIGH SENSITIVITY | TAS Project Co. Ltd. (JP) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690429-A1 | METHOD FOR QUANTITATIVELY DETECTING 8-OXO-2'-DEOXYGUANOSINE IN AQUEOUS SAMPLE SOLUTION WITH HIGH SENSITIVITY | TAS Project Co. Ltd. (JP) | 2014-01-29 | — | — | EP | disclosed |
| EP-2669290-A1 | Nucleic Acid Chemical Modifications | Alnylam Pharmaceuticals Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| WO-2013164802-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-11-07 | — | — | US | disclosed |
| WO-2013161851-A1 | BENZAMIDE DERIVATIVE | 中外製薬株式会社 (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8518966-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130178455-A1 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCES, INC (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013094581-A1 | NOVEL CAMPTOTHECIN DERIVATIVE | 株式会社ヤクルト本社 (JP) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158060-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013089212-A1 | SUBSTITUTED TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 (JP) | 2013-06-20 | — | — | WO | disclosed |
| CN-103153954-A | N-acylsulfonamide apoptosis promoters | ASTRAZENECA AB | 2013-06-12 | — | — | CN | disclosed |
| US-8450414-B2 | Glycerol ester-free functionalized vegetable oil derivatives and their latex compounds | THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2013-05-28 | — | — | US | disclosed |
| CN-101282984-B | Immunogens for meningitis type a vaccines | NOVARTIS AG | 2013-05-08 | — | — | CN | disclosed |
| US-20130078671-A1 | INCORPORATION OF TWO DIFFERENT NONCANONICAL AMINO ACIDS INTO A SINGLE PROTEIN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-28 | — | — | US | disclosed |
| US-8329684-B2 | Cephalosporin derivatives and pharmaceutical compositions thereof | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-12-11 | — | — | US | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-20120264727-A1 | NOVEL CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-10-18 | — | — | US | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2012134184-A2 | NOVEL CEPHALOSPORIN DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 (KR) | 2012-10-04 | — | — | WO | disclosed |
| CN-101805369-B | Preparation methods of distearoyl phosphatidyl ethanolamine and amino polyethylene glycol derivatives thereof | UNIV SOUTHEAST | 2012-10-03 | — | — | CN | disclosed |
| US-8263618-B2 | 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| CN-102653573-A | Anti-adsorption and long-circulation lipid molecule, preparation method and application thereof in fields of medicines and cosmetics | INST PROCESS ENG CAS | 2012-09-05 | — | — | CN | disclosed |
| US-8232309-B2 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2185553-B1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2012-06-27 | — | — | EP | disclosed |
| CN-102516176-A | Indazole derivatives that inhibit TRPVL receptor | ABBOTT LAB | 2012-06-27 | — | — | CN | disclosed |
| CN-102471283-A | Flavin derivatives | BIORELIX INC | 2012-05-23 | — | — | CN | disclosed |
| EP-2433937-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433937-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2403863-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8062641-B2 | Immunogens for meningitidis-A vaccines | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7968707-B2 | Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection | ABBOTT LABORATORIES (US) | 2011-06-28 | — | — | US | disclosed |
| US-7960523-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124677-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2001876-B1 | 8-AZABICYCLOÝ3.2.1¨OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011048409-A1 | CYCLIC AMINE DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | WO | disclosed |
| US-7902221-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-7862807-B2 | Dendrimers as molecular translocators | UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-12-16 | — | — | US | disclosed |
| WO-2010142978-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | WO | disclosed |
| CN-101878208-A | Quinoxaline-type-piperidine compounds that replaces and uses thereof | PURDUE PHARMA LP | 2010-11-03 | — | — | CN | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| CN-101805369-A | Preparation methods of distearoyl phosphatidyl ethanolamine and amino polyethylene glycol derivatives thereof | UNIV SOUTHEAST | 2010-08-18 | — | — | CN | disclosed |
| EP-2185553-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010027280-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-03-11 | — | — | WO | disclosed |
| US-20100035921-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090304734-A1 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2009-12-10 | — | — | US | disclosed |
| US-7622508-B2 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2114866-A2 | GLYCEROL ESTER-FREE FUNCTIONALIZED VEGETABLE OIL DERIVATIVES AND THEIR LATEX COMPOSITIONS | University of Southern Mississippi (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009120878-A2 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-2086958-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090186343-A1 | METHODS FOR PREPARING MODIFIED BIOMOLECULES, MODIFIED BIOMOLECULES AND METHODS FOR USING SAME | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-7550474-B2 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090143527-A1 | Glycerol Ester-Free Functionalized Vegetable Oil Derivatives and Their Latex Compounds | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2009-06-04 | — | — | US | disclosed |
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1408045-B1 | NOVEL GALACTOSYLCERAMIDE ANALOGS AND BETA-GLUCOCEREBROSIDASE ACTIVATORS,EXTERNAL SKIN PREPARATIONS AND METHOD OF ACTIVATING BETA-GLUCOCEREBROSIDASE USING THE ANALOGS | KAO CORP (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-7511125-B2 | Pyrimidine derivatives for labeled binding partners | CARLSBAD (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027679-A1 | PROCESS FOR THE PREPARATION OF GUANIDINO SUBSTITUTED BI-AND POLYPHENYLS THAT ARE SUITABLE AS SMALL MOLECULE CARRIERS | UCL BUSINESS PLC (GB) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2009029252-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7498394-B2 | (Meth)acrylic and (meth)acrylamide monomers, polymerizable compositions, and polymers obtained | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-03-03 | — | — | US | disclosed |
| CN-101365684-A | Indazole derivatives inhibiting TRPV1 receptor | ABBOTT LAB (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-2001876-A2 | 8-AZABICYCLOÝ3.2.1¨OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| CN-101282984-A | Immunogens for meningitidis-a vaccines | NOVARTIS VACCINES & DIAGNOSTIC (IT) | 2008-10-08 | — | — | CN | disclosed |
| EP-1957464-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | Abbott Laboratories (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008094503-A2 | GLYCEROL ESTER-FREE FUNCTIONALIZED VEGETABLE OIL DERIVATIVES AND THEIR LATEX COMPOSITIONS | UNIVERSITY OF SOUTH MISSISSIPPI (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080183000-A1 | Glycerol ester-free functionalized vegetable oil derivatives and their latex compositions | UNIVERSITY OF SOUTHERN MISSISSIPPI, THE | 2008-07-31 | — | — | US | disclosed |
| US-20080176959-A1 | BIODEGRADABLE POLYPHOSPHATES COMPLEX FOR CONTROLLED RELEASE OF BIOACTIVE SUBSTANCES AND RELATED METHODS | JOHNS HOPKINS SINGAPORE PTE LTD (SG) | 2008-07-24 | — | — | US | disclosed |
| US-20080176800-A1 | METHODS FOR THE DELIVERY OF BIOACTIVE SUBSTANCES WITH BIODEGRADABLE POLYPHOSPHATES | JOHNS HOPKINS SINGAPORE PTE LTD (SG) | 2008-07-24 | — | — | US | disclosed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBVIE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| US-7345138-B2 | Biodegradable polyphosphates for controlled release of bioactive substances | JOHNS HOPKINS SINGAPORE PTE LTD. (SG) | 2008-03-18 | — | — | US | disclosed |
| EP-1885734-A2 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | Novartis Vaccines and Diagnostics S.r.l. (IT) | 2008-02-13 | — | — | EP | disclosed |
| US-20080033155-A1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-7288640-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-20 | — | — | US | disclosed |
| WO-2007103187-A2 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| CN-1976932-A | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2007-06-06 | — | — | CN | disclosed |
| US-20070111951-A1 | Novel galactosylceramide analogues, and beta-glucocerebrosidase activator, external skin preparations and method of activating beta-glucocerebrosidase using the same | KAO CORPORATION | 2007-05-17 | — | — | US | disclosed |
| WO-2007050732-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | ABBOTT LABORATORIES (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-7183261-B2 | Galactosylceramide analogs, and β-glucocerebrosidase activators, external skin preparations and method of activating β-glucocerebrosidase using the analogs | KAO CORPORATION (JP) | 2007-02-27 | — | — | US | disclosed |
| WO-2006120576-A2 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2006-11-16 | — | — | WO | disclosed |
| US-20060252900-A1 | (Meth)arcrylic and (meth)acrylamide monomers, polymerizable compositions, and polymers obtained | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2006-11-09 | — | — | US | disclosed |
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-RE39324-E1 | Pyrimidine derivatives and oligonucleotides containing same | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1495129-A4 | HYBRID PHOSPHOINOSITIDE PHOSPHOLIPIDS: COMPOSITIONS AND USES | UNIV UTAH RES FOUND (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2006027211-A1 | 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | WO | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| WO-2006012425-A2 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-0994105-B1 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | PFIZER PROD INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6962942-B2 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6951931-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6924304-B2 | Cell proliferation inhibitors | ABBOTT LABORATORIES (US) | 2005-08-02 | — | — | US | disclosed |
| US-6916948-B2 | Bis(1,3-dihydroxy-prop-2-yl) amine and derivatives thereof in the manufacture of polymers | ISIS INNOVATION LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20050148042-A1 | Hybrid phosphoinositide phospholipids: compositions and uses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-07 | — | — | US | disclosed |
| CN-1207288-C | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2005-06-22 | — | — | CN | disclosed |
| US-20050131200-A1 | Biodegradable polyphosphates for controlled release of bioactive substances | JOHNS HOPKINS SINGAPORE PTE LTD. (SG) | 2005-06-16 | — | — | US | disclosed |
| US-6906094-B2 | 1,2,4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase | WARNER-LAMBERT COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050118605-A9 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | US | disclosed |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6864268-B2 | β3 adrenergic receptor agonists | PFIZER INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | BAKER BRENDA F (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050020826-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1499627-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS Pharmaceuticals, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1495129-A2 | HYBRID PHOSPHOINOSITIDE PHOSPHOLIPIDS: COMPOSITIONS AND USES | The University of Utah Research Foundation (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| EP-1027364-B1 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040242499-A1 | Novel galactosylceramide analogs, and beta-glucocerebrosidase activators, external skin preparations and method of activating beta-glucocerebrosidase using the analogs | KAO CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040241706-A1 | Highly specific modulators of GTPases for target validation | IRM, LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6800743-B2 | FOR USE AS LABELS IN DIAGNOSTIC ASSAYS AND IN ENHANCING BINDING TO COMPLEMENTARY BASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| WO-2004077511-A2 | (METH)ACRYLIC AND (METH)ACRYLAMIDE MONOMERS, POLYMERIZABLE COMPOSITIONS, AND POLYMERS OBTAINED | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040106633-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| EP-1280802-B1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2004-05-06 | — | — | EP | disclosed |
| EP-1408045-A1 | NOVEL GALACTOSYLCERAMIDE ANALOGS AND BETA-GLUCOCEREBROSIDASE ACTIVATORS,EXTERNAL SKIN PREPARATIONS AND METHOD OF ACTIVATING BETA-GLUCOCEREBROSIDASE USING THE ANALOGS | Kanebo, Limited (JP) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004024082-A2 | HIGHLY SPECIFIC MODULATORS OF GTPASES FOR TARGET VALIDATION | IRM, LLC (GB) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053983-A1 | 1, 2, 4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase | BARVIAN NICOLE CHANTEL (US) | 2004-03-18 | — | — | US | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| US-6706021-B2 | ANTICOAGULANT FOR CATHETERS, DIALYSIS MACHINES, SYRINGES, TUBES, BLOOD LINES AND STENTS; TRYPSIN-LIKE SERINE PROTEASES SUCH AS THROMBIN; 3-BENZYLSULFONYLAMINO-6-METHYL-1-((2-GUANIDINOOXYETHYL) AMINOCARBONYLMETHYL)-2-PYRIDINONE | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6696081-B2 | LIPIDS WHERE THE GLYCEROL BACKBONE IS REPLACED WITH A CARBOHYDRATE; CONJUGATES; DRUG DELIVERY | DUKE UNIVERSITY | 2004-02-24 | — | — | US | disclosed |
| US-6696500-B2 | BIOACTIVE SUBSTANCE HAVING ACIDIC GROUP AND A BIODEGRADABLE POLYMER HAVING AN OPTIONALLY PROTECTED BASIC GROUP, SUCH AS A POLYLACTONE THAT HAS BEEN ESTERIFIED, AMIDATED, OR THIOESTERIFIED WITH A COMPOUND HAVING CYCLIC AMINO GROUPS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-0815853-B1 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-21 | — | — | EP | disclosed |
| CN-1469876-A | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists | �Ʒ� | 2004-01-21 | — | — | CN | disclosed |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | ALLEN DARIN ARTHUR (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225115-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030207804-A1 | Modified peptide nucleic acids | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1212300-B1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| CN-1125051-C | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2003-10-22 | — | — | CN | disclosed |
| WO-2003082903-A2 | HYBRID PHOSPHOINOSITIDE PHOSPHOLIPIDS: COMPOSITIONS AND USES | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030175906-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030176677-A1 | Pyrimidine derivatives for labeled binding partners | IONIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6620831-B2 | Cyclin dependent kinase inhibitors; anticarcinogenic and antiinflammatory agents; restenosis, angiogenesis | LG LIFE SCIENCES LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| WO-2003072636-A1 | CATIONIC HIGHLY BRANCHED POLYAMINOESTER | PARK JONG SANG (KR) | 2003-09-04 | — | — | WO | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-20030158403-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2003-08-07 | — | — | US | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | disclosed |
| EP-1280802-A4 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2003-06-11 | — | — | EP | disclosed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-6566379-B1 | As proteolytic enzyme inhibitors; thrombin inhibitors; for therapy of pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema or inflammation in a mammal | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | LIN KUEI-YING (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1294687-A2 | 1,2,4-TRISUBSTITUTED BENZENES AS INHIBITORS OF 15-LIPOXYGENASE | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295874-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6521658-B1 | Cell proliferation inhibitors | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| EP-1280802-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG Life Sciences Ltd. (KR) | 2003-02-05 | — | — | EP | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2003004602-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-1073449-A4 | AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1265897-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002097134-A2 | MODIFIED PEPTIDE NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002092667-A1 | BIODEGRADABLE POLYPHOSPHATES FOR CONTROLLED RELEASE OF BIOACTIVE SUBSTANCES | JOHNS HOPKINS SINGAPORE PTE LTD. (SG) | 2002-11-21 | — | — | WO | disclosed |
| US-6472529-B2 | VIRICIDES | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| US-6472399-B2 | ANTICOAGULANTS; MAY BE EMBEDDED IN OR PHYSICALLY LINKED TO MATERIALS USED IN MANUFACTURE OF DEVICES USED IN BLOOD COLLECTION, CIRCULATION, STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6469029-B1 | INHIBITORS OF THROMBIN PRODUCTION VIA FACTOR XA INHIBITION; COUPLED TO MEDICAL DEVICES, SUCH AS STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-1242366-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6417161-B1 | KETONE AMINO DERIVATIVES | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-07-04 | — | — | US | disclosed |
| US-6414127-B1 | INCREASED AFFINITY TO COMPLEMENTARY OLIGONUCLEOTIDES; DNA SEQUENCING; MEDICAL DIAGNOSIS; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| CN-1353689-A | Novel hydroxamic acid derivatives | DAIICHI PREC KAGAKU (JP) | 2002-06-12 | — | — | CN | disclosed |
| US-20020052465-A1 | Bis(1,3-dihydroxy-prop-2-yl) amine and derivatives thereof in the manufacture of polymers | ISIS INNOVATION LIMITED (GB) | 2002-05-02 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-20020035082-A1 | Carbohydrate based lipid compositions and supramolecular structures comprising same | DUKE UNIVERSITY | 2002-03-21 | — | — | US | disclosed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6350764-B2 | FOR INHIBITING LOSS OF BLOOD PLATELETS; INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, FIBRIN, THROMBUS, AND EMBOLUS; ANTICOAGULANTS EMBEDDED IN DEVICES FOR BLOOD COLLECTION, CIRCULATION, STORAGE (CATHETERS, DIALYSIS MACHINES); STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1179529-A1 | NOVEL HYDROXAMIC ACID DERIVATIVES | Daiichi Fine Chemical Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-0882024-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-01-17 | — | — | US | disclosed |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2002-01-10 | — | — | US | disclosed |
| EP-1170289-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6334890-B1 | COMPOSITION COMPRISED OF OXAZOLINE COMPOUND WITH SPECIFIED MELTING POINT AND ACOUSTIC LOSS VALUE, LONG CHAIN CARBAMATE, ALCOHOL COMPOUND, LIGHTFASTNESS COMPONENT, LIGHTFASTNESS ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2002-01-01 | — | — | US | disclosed |
| WO-2001096298-A2 | 1,2,4-TRISUBSTITUTED BENZENES AS INHIBITORS OF 15-LIPOXYGENASE | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1159255-A2 | BIS(1,3-DIHYDROXY-PROP-2-YL)AMINE AND DERIVATIVES THEREOF IN THE MANUFACTURE OF POLYMERS | ISIS INNOVATION LIMITED (GB) | 2001-12-05 | — | — | EP | disclosed |
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | disclosed |
| WO-2001085726-A1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2001-11-15 | — | — | WO | disclosed |
| US-20010038854-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6313296-B1 | 2-PYRROLIDINONE-1-ACETIC ACID DERIVATIVES; VIRICIDES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV); ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT | ABBOTT LABORATORIES | 2001-11-06 | — | — | US | disclosed |
| EP-1140859-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001070743-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6291489-B1 | USEFUL IN THE SYNTHESIS OF CERTAIN .BETA.-ADRENERGIC RECEPTOR AGONISTS | PFIZER INC. | 2001-09-18 | — | — | US | disclosed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | disclosed |
| US-6288141-B1 | Ink compositions | XEROX CORPORATION | 2001-09-11 | — | — | US | disclosed |
| US-6287373-B1 | FOR ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-09-11 | — | — | US | disclosed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6268338-B1 | USEFUL AS AN ANTIBIOTIC, ESPECIALLY AS AN ANTIFUNGAL AGENT OR AS AN ANTIPROTOZOAL AGENT. | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| US-6264970-B1 | BIODEGRADABLE POLYMER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6245763-B1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6210816-B1 | Translucent xerographic recording substrates | XEROX CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-1086122-A1 | PYRAZINONE PROTEASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0639586-B1 | Phosphonic acid derivatives, process for their preparation and pharmaceutical compositions comprising them | ADIR (FR) | 2001-03-21 | — | — | EP | disclosed |
| US-6204263-B1 | THROMBIN INHIBITORS. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6187082-B1 | COMPOSITION COMPRISED OF THIOUREA AND INK CARBAMATE, EACH WITH SPECIFIED MELTING POINT AND ACOUSTIC-LOSS VALUE, LIGHTFASTNESS COMPONENT, LIGHTFAST ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2001-02-13 | — | — | US | disclosed |
| EP-1073449-A1 | AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| CN-1283189-A | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2001-02-07 | — | — | CN | disclosed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6124457-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| WO-2000055111-A2 | BIS(1,3-DIHYDROXY-PROP-2-YL)AMINE AND DERIVATIVES THEREOF IN THE MANUFACTURE OF POLYMERS | ISIS INNOVATION LIMITED (GB) | 2000-09-21 | — | — | WO | disclosed |
| EP-1036063-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| EP-1027364-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6090942-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0994105-A2 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | Pfizer Products Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-6028183-A | Pyrimidine derivatives and oligonucleotides containing same | GILEAD SCIENCES, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6007992-A | MIXING DERIVATIVE WITH A SAMPLE CONTAINING TARGET NUCLEIC ACIDS, AND INCUBATING FORMING A COMPLEX; FOR DIAGNOSTIC ASSAYS AND TO ENHANCE BINDING TO COMPLEMENTARY BASES | GILEAD SCIENCES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999064446-A1 | PYRAZINONE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999055355-A1 | AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5977124-A | β-adrenergic agonists | PFIZER INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0938476-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1999024452-A9 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS INC (US) | 1999-08-12 | — | — | WO | disclosed |
| US-5929120-A | Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption | MERCK & CO., INC. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| US-5914313-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0920864-A1 | Combination therapy including a specific beta-3 agonist and an anorectic agent | Pfizer Products Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999026926-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999024452-A2 | PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS | ISIS PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0793641-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-04-21 | — | — | EP | disclosed |
| CN-1208405-A | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 1999-02-17 | — | — | CN | disclosed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0882024-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0876353-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0683676-A4 | DIRECTED BIODISTRIBUTION OF SMALL MOLECULES. | NEORX CORP (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5783564-A | Sialic acid derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-07-21 | — | — | US | disclosed |
| WO-1998021184-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5741796-A | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption | MERCK & CO., INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0659762-B1 | Sialic acid derivatives | MITSUBISHI CHEM CORP (JP) | 1998-04-01 | — | — | EP | disclosed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5712254-A | ALZHEIMER'S DISEASE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-01-27 | — | — | US | disclosed |
| EP-0707488-A4 | CYCLOHEXAPEPTIDYL AMINE COMPOUNDS | MERCK & CO INC (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0815853-A2 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0760658-A4 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0793641-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-09-10 | — | — | EP | disclosed |
| US-5643878-A | TREATMENT OF RETROVIRAL DISEASES LIKE AIDS | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021683-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0760658-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO. INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| CN-1144801-A | Beta-Adrenergic agonists | PFIZER (US) | 1997-03-12 | — | — | CN | disclosed |
| US-5607659-A | Directed biodistribution of radiolabelled biotin using carbohydrate polymers | NEORX CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| US-5608045-A | DISODIUM SALT BY POT REACTING RHAMNOSE TRIACETATE WITH PHENYL DICHLOROPHOSPHATE IN PRESENCE OF TRIETHYLAMINE AND WITH /S/LEU-/S/TRP-OET IN SOLVENT, SAPONIFYING SEPARATED PRODUCT WITH ETHANOLIC BASE IN COLD, EVAPORATING ETHANOL | ADIR ET COMPAGNIE (FR) | 1997-03-04 | — | — | US | disclosed |
| US-5591728-A | ENZYME INHIBITORS WITH AMIDE AND ESTER GROUPS | ADIR ET COMPAGNIE (FR) | 1997-01-07 | — | — | US | disclosed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| US-5541160-A | ECHINOCANDINS | MERCK & CO., INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1996016931-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| EP-0707488-A1 | CYCLOHEXAPEPTIDYL AMINE COMPOUNDS | MERCK & CO. INC. (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0701561-A1 | DESOXYAZAPHOSPHOLIPID DERIVATIVES HAVING INHIBITING ACTIVITY ON PHOSPHOLIPASE A2 | LABORATORIOS MENARINI S.A. (ES) | 1996-03-20 | — | — | EP | disclosed |
| US-5481030-A | USED AS AN ENDOTHELIN CONVERTASE INHIBITOR | ADIR ET COMPAGNIE (FR) | 1996-01-02 | — | — | US | disclosed |
| WO-1995032710-A1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| EP-0683676-A1 | DIRECTED BIODISTRIBUTION OF SMALL MOLECULES | NEORX CORPORATION (US) | 1995-11-29 | — | — | EP | disclosed |
| EP-0659762-A2 | Sialic acid derivatives | Mitsubishi Chemical Corporation (JP) | 1995-06-28 | — | — | EP | disclosed |
| EP-0389437-B1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0639586-A1 | Phosphonic acid derivatives, process for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 1995-02-22 | — | — | EP | disclosed |
| WO-1994028004-A1 | DESOXYAZAPHOSPHOLIPID DERIVATIVES HAVING INHIBITING ACTIVITY ON PHOSPHOLIPASE A2 | LABORATORIOS MENARINI S.A. (ES) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994025048-A1 | CYCLOHEXAPEPTIDYL AMINE COMPOUNDS | MERCK & CO., INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| US-5346887-A | Mixture of tripeptide renin inhibitor and steroid antiinflammatory agent | ABBOTT LABORATORIES (US) | 1994-09-13 | — | — | US | disclosed |
| WO-1994017829-A1 | DIRECTED BIODISTRIBUTION OF SMALL MOLECULES | NEORX CORPORATION (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994009033-A1 | AN IMPROVED PROCESS FOR CYCLOHEXAPEPTIDYL BISAMINE COMPOUNDS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5304650-A | Reacting chloroformates with amino alcohol derivatives in aqueous alkali metal hydroxide solution | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-19 | — | — | US | disclosed |
| US-5243035-A | Drug delivery | DRUG DELIVERY SYSTEM INSTITUTE, LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5166135-A | Administering cyclohexapeptide antibiotic; AIDS | MERCK & COMPANY, INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-5128069-A | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0489162-A1 | DERIVATIVE OF GLYCOLIPID CONTAINING SIALIC ACID | DRUG DELIVERY SYSTEM INSTITUTE, LTD. (JP) | 1992-06-10 | — | — | EP | disclosed |
| US-5059589-A | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0415981-A4 | RETROVIRAL PROTEASE INHIBITORS | — | 1991-10-09 | — | — | EP | disclosed |
| US-5036051-A | Renin inhibitors | ABBOTT LABORATORIES (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0415981-A1 | RETROVIRAL PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0389437-A1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4927807-A | RENIN INHIBITING AMIDES | ABBOTT LABORATORIES (US) | 1990-05-22 | — | — | US | disclosed |
| EP-0342541-A2 | Retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1989-11-23 | — | — | EP | disclosed |
| WO-1989010752-A1 | RETROVIRAL PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
| EP-0311012-A2 | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0309422-A2 | New amidino tricycle derivatives | ISTITUTO DE ANGELI S.p.A. (IT) | 1989-03-29 | — | — | EP | disclosed |
| US-4698231-A | Sweetening with L-aminodicarboxylic acid amides | GENERAL FOOD CORPORATION (US) | 1987-10-06 | — | — | US | disclosed |
| US-4622418-A | LOW CALORIE SWEETENERS | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| JP-S61246196-A | 5'-O-ACYL-5-FLUOROURIDINE AND PRODUCTION THEREOF | FUJI KAGAKU KOGYO KK | 1986-11-01 | — | — | JP | disclosed |
| US-4461761-A | IMMUNO-REGULATORS | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1984-07-24 | — | — | US | disclosed |
| JP-S5849395-A | NOVEL NITROSOUREA COMPOUND | SUAMI TETSUO | 1983-03-23 | — | — | JP | disclosed |
| US-4180565-A | ANTIBACTERIAL AGENTS, ANTIBIOTICS | SCHERING CORPORATION (US) | 1979-12-25 | — | — | US | disclosed |
| US-4092324-A | ANTIARTERIOSCLEROSIS AGENTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-05-30 | — | — | US | disclosed |
| US-4008265-A | ANTIARTERIOSCLEROSIS | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-02-15 | — | — | US | disclosed |
| US-4008265-A | ANTIARTERIOSCLEROSIS | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | LMNA 3047/4885SMN1; SMN2 234/4885HTT 1189/4885 |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | LMNA 1468/4885SMN1; SMN2 2178/4885HTT 3936/4885 |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | LMNA 2734/4885SMN1; SMN2 612/4885HTT 354/4885 |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | LMNA 647/4885SMN1; SMN2 702/4885HTT 2307/4885 |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | LMNA 3159/4885SMN1; SMN2 1508/4885HTT 4456/4885 |
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | LMNA 145/4885SMN1; SMN2 49/4885HTT 247/4885 |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | LMNA 3650/4885SMN1; SMN2 1134/4885HTT 820/4885 |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | LMNA 677/4885SMN1; SMN2 3644/4885HTT 2709/4885 |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | LMNA 839/4885SMN1; SMN2 636/4885HTT 3326/4885 |
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | SERPINB1, PREP, DNPEP | LMNA 3494/4885SMN1; SMN2 2544/4885HTT 3582/4885 |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | LMNA 3313/4885SMN1; SMN2 96/4885HTT 4852/4885 |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | LMNA 3047/4885SMN1; SMN2 234/4885HTT 1189/4885 |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | LMNA 1399/4885SMN1; SMN2 1957/4885HTT 2909/4885 |
| US-20080183000-A1 | Glycerol ester-free functionalized vegetable oil derivatives and their latex compositions | HDHD5, MGLL, ABHD6 | LMNA 1572/4885SMN1; SMN2 1706/4885HTT 95/4885 |
| US-12552775-B2 | Compounds and uses thereof | SMARCC1, SMARCC2, CHD1 | LMNA 341/4885SMN1; SMN2 238/4885HTT 1809/4885 |
| US-10905681-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | LMNA 3313/4885SMN1; SMN2 96/4885HTT 4852/4885 |
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | LMNA 1281/4885SMN1; SMN2 2563/4885HTT 2282/4885 |
| US-20170349578-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | LMNA 4153/4885SMN1; SMN2 1535/4885HTT 3976/4885 |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | LMNA 3313/4885SMN1; SMN2 96/4885HTT 4852/4885 |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | LMNA 2305/4885SMN1; SMN2 3262/4885HTT 773/4885 |
| US-20200246264-A1 | POLYMERIC DRUG DELIVERY SYSTEMS FOR TREATMENT OF DISEASE | VHL, IAPP, KRAS | LMNA 1858/4885SMN1; SMN2 8/4885HTT 124/4885 |
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | LMNA 1148/4885SMN1; SMN2 3474/4885HTT 4046/4885 |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | LMNA 2734/4885SMN1; SMN2 612/4885HTT 354/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885SMN1; SMN2 2647/4885HTT 2464/4885 |
| US-20160176863-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | LMNA 4153/4885SMN1; SMN2 1535/4885HTT 3976/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | LMNA 2428/4885SMN1; SMN2 111/4885HTT 2741/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LMNA 4516/4885SMN1; SMN2 4757/4885HTT 1193/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | LMNA 3313/4885SMN1; SMN2 96/4885HTT 4852/4885 |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | LMNA 3650/4885SMN1; SMN2 1134/4885HTT 820/4885 |
| US-20080176800-A1 | METHODS FOR THE DELIVERY OF BIOACTIVE SUBSTANCES WITH BIODEGRADABLE POLYPHOSPHATES | TNNC1, PYGM, MYO3A | LMNA 388/4885SMN1; SMN2 786/4885HTT 4097/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | LMNA 2559/4885SMN1; SMN2 36/4885HTT 4846/4885 |
| US-20020035082-A1 | Carbohydrate based lipid compositions and supramolecular structures comprising same | SGMS1, SLC2A8, SLC27A1 | LMNA 2038/4885SMN1; SMN2 1904/4885HTT 4768/4885 |
| US-20040241706-A1 | Highly specific modulators of GTPases for target validation | CDC42, ARHGDIB, ARHGEF2 | LMNA 3356/4885SMN1; SMN2 2700/4885HTT 2471/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | LMNA 2930/4885SMN1; SMN2 1850/4885HTT 1424/4885 |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | LMNA 4153/4885SMN1; SMN2 1535/4885HTT 3976/4885 |
| US-20030225115-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, F2R | LMNA 1435/4885SMN1; SMN2 3824/4885HTT 1042/4885 |
| US-20030072712-A1 | Pyrimidine derivatives for labeled binding partners | DDB1, RRBP1, PRPF31 | LMNA 1399/4885SMN1; SMN2 1763/4885HTT 1385/4885 |
| US-10961278-B2 | Vancomycin derivative, preparation method, pharmaceutical composition and use thereof | PEPD, VIP, NRDC | LMNA 2535/4885SMN1; SMN2 3904/4885HTT 3175/4885 |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | LMNA 4153/4885SMN1; SMN2 1535/4885HTT 3976/4885 |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | LMNA 1304/4885SMN1; SMN2 1782/4885HTT 3784/4885 |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | LMNA 4153/4885SMN1; SMN2 1535/4885HTT 3976/4885 |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, TFPI, TFPI2 | LMNA 2021/4885SMN1; SMN2 4416/4885HTT 2422/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | LMNA 3687/4885SMN1; SMN2 3657/4885HTT 1767/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | LMNA 3313/4885SMN1; SMN2 96/4885HTT 4852/4885 |
| US-20230099027-A1 | VIRUCIDAL COMPOSITIONS AND USE THEREOF | NEU3, NEU1, SIGLEC9 | LMNA 817/4885SMN1; SMN2 2748/4885HTT 2140/4885 |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | LMNA 1332/4885SMN1; SMN2 2100/4885HTT 3679/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885SMN1; SMN2 2647/4885HTT 2464/4885 |
| US-20230055805-A1 | TOLL-LIKE RECEPTOR LIGANDS | TLR1, TLR4, TLR6 | LMNA 3915/4885SMN1; SMN2 2055/4885HTT 3659/4885 |
| US-20180280491-A1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | CD4, CSGALNACT1, B3GNT2 | LMNA 4178/4885SMN1; SMN2 4716/4885HTT 2633/4885 |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | LMNA 3875/4885SMN1; SMN2 4797/4885HTT 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.